Summary

In a Phase 3 study comparing tedizolid, a second generation oxazolidinone, to linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI), tedizolid phosphate was noninferior and demonstrated high microbiological efficacy compared with linezolid. This article presents a poster [De Anda et al. ICAAC 2012 L1–1665] on the outcomes using the the new Food and Drug Administration method for assessing clinical response, programmatic assessment, and the traditional post-treatment investigator assessment.